Tuesday, October 08, 2019 08:52 PM

JOHNSON & JOHNSON'S NOD FOR PROSTATE CANCER DRUG MAY OFFER HOPE TO SPECIFIC PATIENTS - SEEKING ALPHA

Johnson & Johnson (JNJ[1]) announced that it had obtained FDA approval for its prostate cancer drug known as Erleada[2]. This will allow the company to target more of the metastatic prostate cancer market. However, it's been having trouble competing against Pfizer (PFE[3]) and Astellas in other indications for those with prostate cancer. However, patients with metastatic castration-sensitive prostate cancer had greatly benefited from treatment with Erleada. Especially, when you consider that, at the beginning of the year, a phase 3 study was stopped early due to highly positive efficacy. While Johnson & Johnson has a major competitor for its drug Erleada, this approval is a win nonetheless. Plus, it also had another prostate cancer drug known as Zytiga, which has been performing well.

FDA Supplemental Approval Adds To Erleada's Target Indications

The FDA approved the supplemental new drug application (sNDA) for Erleada along with androgen deprivation therapy (ADT). This is an important approval, because it will target a population that really ...

News source: GOOGLE NEWS

See also: Associated Urologists Nashville